SeaBeLife secures €1.2m in funding
Biotech company, specialising in cell necrosis prevention, has announced a successful funding round, securing €1.2m in additional seed funding.
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death pathways. The funding comes from the iXLife fund and a group of historical investors, including Breizh Angels, Angels Santé, WeLike, and BAdGE, who have already supported the company with contributions of €1.6m in seed funding since 2020. “We are convinced that this one-of-a-kind approach has the potential to protect cells affected by certain disorders, including acute liver disease. Clinical development in this indication is due to kick off in 2024”, said Professor Jean-Pierre Kinet, chairman and director of the iXLife fund.
The company’s focus lies in addressing conditions such as acute liver disease and eye disorders. It will also facilitate team expansion, enabling SeaBeLife to recruit high-level specialists for the setup of clinical trials. The company’s plans include the launch of a Phase I trial for severe hepatitis in 2024, as well as strategic partnerships with pharmaceutical companies involved in eye disorders. SeaBeLife aims to optimise its drug candidates for potential use in treating neurodegenerative diseases by 2025. Professor Kinet, will join SeaBeLife’s strategic committee, bringing valuable expertise. SeaBeLife also plans to expand its technology for neurodegenerative disease treatment by 2025, and they are preparing for Series A fundraising to further develop their innovative approach.
